[
    {
        "file_name": "ArrayBioPharmaInc.-LICENSE,DEVELOPMENTANDCOMMERCIALIZATIONAGREEMENT.txt",
        "perturbation": [
            {
                "type": "Omissions - In Text Contradiction",
                "original_text": "1.14  \"Development\" or \"Develop\" means non-clinical and clinical research and drug development activities, including toxicology, pharmacology, statistical analysis, Clinical Studies (including pre- and post-approval studies, Post-Approval Marketing Clinical Studies and Investigator Sponsored Clinical Studies), stability testing, formulation, process development, quality assurance/control development, regulatory affairs, and regulatory activities pertaining to designing and carrying out Clinical Studies and obtaining and maintaining Marketing Approvals (including pre-marketing activities but excluding regulatory activities directed to obtaining Pricing and Reimbursement Approvals).",
                "changed_text": "1.14  \"Development\" or \"Develop\" means non-clinical and clinical research and drug development activities, including toxicology, pharmacology, statistical analysis, stability testing, formulation, process development, quality assurance/control development, regulatory affairs, and regulatory activities pertaining to designing and carrying out research and obtaining and maintaining regulatory approvals (including pre-marketing activities but excluding regulatory activities directed to obtaining Pricing and Reimbursement Approvals).",
                "explanation": "Removing 'Clinical Studies' creates an internal contradiction because other sections, such as Article IV, heavily rely on the definition of Development including Clinical Studies. This omission introduces ambiguity regarding the scope of development activities covered under the agreement and creates uncertainty as to whether the listed activities should be performed.",
                "location": "ARTICLE I DEFINITIONS"
            },
            {
                "type": "Omissions - In Text Contradiction",
                "original_text": "1.25  \"Good Manufacturing Practices or \"GMP\" means all laws and guidelines applicable to the Manufacture of Binimetinib, Encorafenib or Product, including (i) the FD&C Act (21 U.S.C. 321 et seq.); (ii) relevant United States regulations in Title 21 of the United States Code of Federal Regulations (including Parts 11, 210, and 211); (iii) European Community Directives 2001/83/EC and 2003/94/EC; (iv) the EU Guidelines to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use, as set out in Volume 4 of the European Commission's Rules governing medicinal products in the EU; (v) those standards required by the Japanese Ministry of Health Labour and Welfare (MHLW); (vi) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (\"ICH\"), Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients; (vii) similar standards and Laws to those in (i) through (vi), as are in effect at the time of Manufacture; and (viii) all additional Regulatory Authority documents or regulations that replace, amend, modify, supplant or complement any of the foregoing.",
                "changed_text": "1.25  \"Good Manufacturing Practices or \"GMP\" means all laws and guidelines applicable to the Manufacture of Binimetinib, Encorafenib or Product, including (i) the FD&C Act (21 U.S.C. 321 et seq.); (ii) relevant United States regulations in Title 21 of the United States Code of Federal Regulations (including Parts 11, 210, and 211); (iii) European Community Directives 2001/83/EC and 2003/94/EC; (iv) the EU Guidelines to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use, as set out in Volume 4 of the European Commission's Rules governing medicinal products in the EU; (v) those standards required by the Japanese Ministry of Health Labour and Welfare (MHLW); (vi) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (\"ICH\"), Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients; (vii) similar standards and Laws to those in (i) through (vi), as are in effect at the time of Manufacture.",
                "explanation": "Omission of 'and (viii) all additional Regulatory Authority documents or regulations that replace, amend, modify, supplant or complement any of the foregoing' creates an internal contradiction because the definition no longer includes future updates or changes to GMP regulations. This omission introduces uncertainty as to which GMP standards apply if the cited regulations are updated, creating uncertainty in the enforcement of manufacturing standards.",
                "location": "ARTICLE I DEFINITIONS"
            },
            {
                "type": "Omissions - In Text Contradiction",
                "original_text": "8.2 Exclusivity of Efforts. Prior to the [ * ], neither Ono or its Affiliates, nor Array or its Controlled Affiliates, shall Commercialize in the Ono Territory: (i) a product that includes, as an active pharmaceutical ingredient, an agent that is a [ * ] (other than Binimetinib), or (ii) a product that includes, as an active pharmaceutical ingredient, an agent that is a [ * ] (other than Encorafenib), or grant the right to a licensee or distributor to Commercialize in the Ono Territory any of the above described products (each a \"Competing Product\"). In addition, in the event that Array terminates this Agreement for Ono's breach pursuant to Section 13.3 during the [ * ], or Ono exercises its right to terminate this Agreement \"at will\" pursuant to Section 13.2 during the Initial Royalty Term, then neither Ono nor its Affiliates shall Commercialize a Competing Product or grant the right to a licensee or distributor to Commercialize a Competing Product in the Ono Territory prior to the [ * ] anniversary of the date such termination takes effect. If during the [ * ], Array Commercializes a Competing Product in the Ono Territory, the royalty payment period shall terminate and Ono may continue to Commercialize the Product. If Ono Commercializes a Competing Product in the Ono Territory during [ * ], Array may immediately terminate this Agreement. As used herein, (i) \"[ * ]\" means a compound that [ * ], and (ii) \"[ * ]\" means a compound that [ * ]. For the avoidance of doubt, [ * ] and [ * ] shall not include a [ * ].",
                "changed_text": "8.2 Exclusivity of Efforts. Prior to the [ * ], neither Ono or its Affiliates, nor Array or its Controlled Affiliates, shall Commercialize in the Ono Territory: (i) a product that includes, as an active pharmaceutical ingredient, an agent that is a [ * ] (other than Binimetinib), or (ii) a product that includes, as an active pharmaceutical ingredient, an agent that is a [ * ] (other than Encorafenib), or grant the right to a licensee or distributor to Commercialize in the Ono Territory any of the above described products (each a \"Competing Product\"). In addition, in the event that Array terminates this Agreement for Ono's breach pursuant to Section 13.3 during the [ * ], or Ono exercises its right to terminate this Agreement \"at will\" pursuant to Section 13.2 during the Initial Royalty Term, then neither Ono nor its Affiliates shall Commercialize a Competing Product or grant the right to a licensee or distributor to Commercialize a Competing Product in the Ono Territory prior to the [ * ] anniversary of the date such termination takes effect. If during the [ * ], Array Commercializes a Competing Product in the Ono Territory, the royalty payment period shall terminate and Ono may continue to Commercialize the Product. As used herein, (i) \"[ * ]\" means a compound that [ * ], and (ii) \"[ * ]\" means a compound that [ * ]. For the avoidance of doubt, [ * ] and [ * ] shall not include a [ * ].",
                "explanation": "Removing the sentence \"If Ono Commercializes a Competing Product in the Ono Territory during [ * ], Array may immediately terminate this Agreement\" creates an in-text contradiction with the rest of the section, which outlines the exclusivity of efforts. With the sentence removed, there is no direct consequence for Ono commercializing a competing product during the [ * ] period, contradicting the stated intent of the section to prevent such commercialization.",
                "location": "ARTICLE VIII CERTAIN COVENANTS"
            }
        ]
    }
]